JP2018509424A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509424A5
JP2018509424A5 JP2017548170A JP2017548170A JP2018509424A5 JP 2018509424 A5 JP2018509424 A5 JP 2018509424A5 JP 2017548170 A JP2017548170 A JP 2017548170A JP 2017548170 A JP2017548170 A JP 2017548170A JP 2018509424 A5 JP2018509424 A5 JP 2018509424A5
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
alkynyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017548170A
Other languages
English (en)
Japanese (ja)
Other versions
JP6676650B2 (ja
JP2018509424A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/020397 external-priority patent/WO2016148674A1/en
Publication of JP2018509424A publication Critical patent/JP2018509424A/ja
Publication of JP2018509424A5 publication Critical patent/JP2018509424A5/ja
Application granted granted Critical
Publication of JP6676650B2 publication Critical patent/JP6676650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017548170A 2015-03-13 2015-03-13 疾患を処置するためのコンジュゲート Active JP6676650B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/020397 WO2016148674A1 (en) 2015-03-13 2015-03-13 Conjugates for treating diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020043256A Division JP2020117509A (ja) 2020-03-12 2020-03-12 疾患を処置するためのコンジュゲート

Publications (3)

Publication Number Publication Date
JP2018509424A JP2018509424A (ja) 2018-04-05
JP2018509424A5 true JP2018509424A5 (https=) 2018-05-24
JP6676650B2 JP6676650B2 (ja) 2020-04-08

Family

ID=56920017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548170A Active JP6676650B2 (ja) 2015-03-13 2015-03-13 疾患を処置するためのコンジュゲート

Country Status (6)

Country Link
US (2) US10624972B2 (https=)
EP (1) EP3268046A4 (https=)
JP (1) JP6676650B2 (https=)
CN (1) CN107847609A (https=)
CA (1) CA2979527A1 (https=)
WO (1) WO2016148674A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266303A1 (en) * 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
WO2017172930A1 (en) * 2016-03-29 2017-10-05 Endocyte, Inc. Pbd conjugates for treating diseases
AU2017271550B2 (en) * 2016-05-25 2023-11-02 Endocyte, Inc. Method of treating cancer by targeting myeloid-derived suppressor cells
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR20210086557A (ko) 2019-12-31 2021-07-08 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体,その製造法および抗腫瘍剤
EP0457875A4 (en) 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0547163B1 (en) 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
AUPN449295A0 (en) * 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
JP4813712B2 (ja) * 1999-08-09 2011-11-09 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN101287500A (zh) * 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
BRPI0615354A2 (pt) * 2005-08-19 2011-05-17 Endocyte, Inc. conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
EP2125870A4 (en) 2007-02-16 2011-04-06 Boehringer Ingelheim Int INHIBITORS OF HEPATITIS C NS3 PROTEASE
CN101784565B (zh) * 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
ES3029483T3 (en) 2008-09-17 2025-06-24 Endocyte Inc Folate receptor binding conjugates of antifolates
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
BR112012029458A2 (pt) 2010-05-19 2015-10-20 Endocyte Inc processo aperfeiçoado para um agente de folato alvejado
JP5826863B2 (ja) * 2011-02-15 2015-12-02 イミュノジェン・インコーポレーテッド 細胞傷害性ベンゾジアゼピン誘導体
US20130267522A1 (en) * 2012-03-01 2013-10-10 Endocyte, Inc. Methods for treating cancer
BR112015008365A2 (pt) * 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
EA201590783A1 (ru) * 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
CA2891280C (en) * 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
LT3191135T (lt) 2014-09-12 2020-11-25 Genentech, Inc. Anti-her2 antikūnai ir imunokonjugatai
US20170266303A1 (en) 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
WO2017172930A1 (en) 2016-03-29 2017-10-05 Endocyte, Inc. Pbd conjugates for treating diseases

Similar Documents

Publication Publication Date Title
JP2018509424A5 (https=)
JP2020525429A5 (https=)
US10040783B2 (en) Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
RU2012115851A (ru) Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2
JP2018510850A5 (https=)
JP2011525509A5 (https=)
JP2020536091A5 (https=)
JP2020517616A5 (https=)
NZ701290A (en) Pyrrolobenzodiazepines
JP2017536344A5 (https=)
JP2018504379A5 (https=)
UA100132C2 (en) Isoxazolo-pyridine derivatives
JP2012516896A5 (https=)
JP2011515397A5 (https=)
JP2017532360A5 (https=)
JP2015502979A5 (https=)
JP2017526662A5 (https=)
JP2018525399A5 (https=)
JP2021519262A5 (https=)
JP6676650B2 (ja) 疾患を処置するためのコンジュゲート
JP2020534300A5 (https=)
CA3250773A1 (en) PROCESS FOR THE SYNTHESIS OF QUINAZOLINE COMPOUNDS
EA201170150A1 (ru) Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона
RU2007143509A (ru) Производные ацетилена
AU2025267403A1 (en) Prostaglandin receptor ep2 antagonists, derivatives, and uses related thereto